Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

The Metabolic and Molecular Bases of Inherited Disease

Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101 · see citing works

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761 · see citing works

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 921 · see citing works

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744 · see citing works

Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review

Austin, M. A. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh236 · Cited by 657 · see citing works

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.03.001 · Cited by 622 · see citing works

Mechanisms of disease: genetic causes of familial hypercholesterolemia

Soutar, A. K., & Naoumova, R. P. (2007) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0836 · Cited by 608 · see citing works

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

Talmud, P. J., Shah, S. H., Whittall, R., Futema, M., Howard, P., Cooper, J. A., Harrison, S. C., Li, K., Drenos, F., Karpe, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62127-8 · Cited by 590 · see citing works

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580 · see citing works

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 575 · see citing works

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Goldberg, A. C., Hopkins, P. N., Toth, P. P., Ballantyne, C. M., Rader, D. J., Robinson, J. G., Daniels, S. R., Gidding, S. S., de Ferranti, S. D., Ito, M. K., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.04.003 · Cited by 545 · see citing works

A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

S, M. G. B., Rader, D. J., Muller, D. W., Kolansky, D. M., Kozarsky, K., Clark, B. J., Stein, E. A., Lupien, P. J., Brewer, H. B., Raper, S. E., et al. (1995) · Nature Medicine · doi:10.1038/nm1195-1148 · Cited by 532 · see citing works

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Raal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 502 · see citing works

Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia

Gagné, C., Gaudet, D., & Bruckert, É. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 480 · see citing works

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

Sjouke, B., Kusters, D. M., Kindt, I., Besseling, J., Defesche, J. C., Sijbrands, E. J. G., van Lennep, J. E. R., Stalenhoef, A. F. H., Wiegman, A., Graaf, J. D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu058 · Cited by 442 · see citing works

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.11.025 · Cited by 377 · see citing works

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

Raal, F. J., Pilcher, G. J., Panz, V. R., van Deventer, H. E., Brice, B. C., Blom, D. J., & Marais, A. D. (2011) · Circulation · doi:10.1161/circulationaha.111.042523 · Cited by 366 · see citing works

Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment

Raal, F. J., & Santos, R. D. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.02.019 · Cited by 349 · see citing works

Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

Stein, E. A., Honarpour, N., Wasserman, S. M., Xu, F., Scott, R. C., & Raal, F. J. (2013) · Circulation · doi:10.1161/circulationaha.113.004678 · Cited by 330 · see citing works

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

Stein, E. A., Dufour, R., Gagné, C., Gaudet, D., East, C. A., Donovan, J. M., Chin, W., Tribble, D. L., & McGowan, M. P. (2012) · Circulation · doi:10.1161/circulationaha.112.104125 · Cited by 297 · see citing works

Recommendations for the use of LDL apheresis

Thompson, G. R. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.009 · Cited by 270 · see citing works

Multiple functions of microsomal triglyceride transfer protein

Hussain, M. M., Rava, P., Walsh, M. T., Rana, M., & Iqbal, J. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-14 · Cited by 261 · see citing works

High Body Mass Index and Hypercholesterolemia

Thadhani, R., STAMPFER, M. J., HUNTER, D. J., MANSON, J. E., SOLOMON, C. G., & CURHAN, G. C. (1999) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(99)00400-7 · Cited by 200 · see citing works

Longitudinal Evaluation and Assessment of Cardiovascular Disease in Patients With Homozygous Familial Hypercholesterolemia

Kolansky, D. M., Cuchel, M., Clark, B. J., Paridon, S., McCrindle, B. W., Wiegers, S. E., Araujo, L. I., Vohra, Y., Defesche, J. C., Wilson, J. M., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.07.035 · Cited by 182 · see citing works

Guidelines for the Management of Familial Hypercholesterolemia

Harada‐Shiba, M., Arai, H., Oikawa, S., Ohta, T., Okada, T., Okamura, T., Nohara, A., Bujo, H., Yokote, K., Wakatsuki, A., et al. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14621 · Cited by 176 · see citing works

Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia

Moorjani, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90815-x · Cited by 172 · see citing works

Clinical pharmacological properties of mipomersen ( K ynamro), a second generation antisense inhibitor of apolipoprotein B

Crooke, S. T., & Geary, R. S. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04469.x · Cited by 171 · see citing works

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

Watts, G. F., Gidding, S. S., Wierzbicki, A. S., Toth, P. P., Rodrigo Alonso, K., Brown, W. V., Bruckert, É., Defesche, J. C., Lin, K. K., Livingston, M., et al. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.01.002 · Cited by 163 · see citing works

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy

Bertolini, S., Pisciotta, L., Rabacchi, C., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.01.007 · Cited by 150 · see citing works

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy

Raal, F. J., Panz, V. R., Immelman, A., & Pilcher, G. J. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.112.000028 · Cited by 132 · see citing works

Relation of cholesterol-year score to severity of calcific atherosclerosis and tissue deposition in homozygous familial hypercholesterolemia

Schmidt, H., Hill, S. C., Makariou, E. V., Feuerstein, I. M., Dugi, K. A., & Hoeg, J. M. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89309-5 · Cited by 124 · see citing works

Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis

Kidambi, S., & Patel, S. B. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.049775 · Cited by 111 · see citing works

Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): A phenotypic comparison

Pisciotta, L., Oliva, C. P., Pes, G. M., Scala, L. D., Bellocchio, A., Fresa, R., Cantàfora, A., Arca, M., Calandra, S., & Bertolini, S. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.11.016 · Cited by 100 · see citing works

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia

Raal, F. J., Pilcher, G. J., Illingworth, D. R., Pappu, A. S., Stein, E. A., Laskarzewski, P. M., Mitchel, Y., & Melino, M. R. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00168-8 · Cited by 98 · see citing works

Vascular Calcifications in Homozygote Familial Hypercholesterolemia

Awan, Z. A., Al‐Rasadi, K., Francis, G. A., Hegele, R. A., McPherson, R., Frohlich, J., Valenti, D. A., de Varennes, B., Marcil, M., Gagné, C., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.160408 · Cited by 98 · see citing works

Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia

Raal, F. J., Pappu, A. S., Illingworth, D. R., Pilcher, G. J., Marais, A. D., Firth, J. C., Kotze, M. J., Heinonen, T. M., & Black, D. M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00435-9 · Cited by 96 · see citing works

Evaluation of the Aortic Root by MRI

Summers, R. M., Andrasko-Bourgeois, J., Feuerstein, I. M., et al. (1998) · Circulation · doi:10.1161/01.cir.98.6.509 · Cited by 91 · see citing works

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

Marais, A. D., Raal, F. J., Stein, E. A., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.06.028 · Cited by 91 · see citing works

Cerebrotendinous xanthomatosis

Björkhem, I. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328362df13 · Cited by 90 · see citing works

Long-Term Safety and Efficacy of Low-Density Lipoprotein Apheresis in Childhood for Homozygous Familial Hypercholesterolemia

Hudgins, L. C., Kleinman, B. M., Scheuer, A., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.06.049 · Cited by 86 · see citing works

Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia

Græsdal, A., Bogsrud, M. P., Holven, K. B., et al. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.03.004 · Cited by 73 · see citing works

Challenges in pediatric transplantation: The impact of chronic kidney disease and cardiovascular risk factors on long‐term outcomes and recommended management strategies

Filler, G. (2010) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2010.01439.x · Cited by 73 · see citing works

Adeno-Associated Virus Serotype 8 Gene Therapy Leads to Significant Lowering of Plasma Cholesterol Levels in Humanized Mouse Models of Homozygous and Heterozygous Familial Hypercholesterolemia

Kassim, S. H., Li, H., Bell, P. L., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.108 · Cited by 72 · see citing works

Lipoprotein apheresis: State of the art and novelties

Stefanutti, C., & Julius, U. (2013) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2012.10.021 · Cited by 72 · see citing works

Cardiac CT angiography in children with congenital heart disease

Siripornpitak, S., Pornkul, R., Khowsathit, P., et al. (2011) · European Journal of Radiology · doi:10.1016/j.ejrad.2011.11.042 · Cited by 71 · see citing works

Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial Hypercholesterolemia

Widhalm, K., Binder, C., Kreissl, A., Aldover‐Macasaet, E., Fritsch, M., Kroisboeck, S., & Geiger, H. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.06.027 · Cited by 67 · see citing works

Premature atherosclerosis is not systematic in phytosterolemic patients: Severe hypercholesterolemia as a confounding factor in five subjects

Hansel, B., Carrié, A., Brun-Druc, N., Leclert, G., Chantepie, S., Coiffard, A.-S., Kahn, J.-F., Chapman, M. J., & Bruckert, É. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.030 · Cited by 67 · see citing works

Preemptive liver transplantation in a child with familial hypercholesterolemia

Maiorana, A., Nobili, V., Calandra, S., et al. (2010) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2010.01383.x · Cited by 64 · see citing works

Effects of the Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib on Apolipoprotein B100 Metabolism in Humans

Millar, J. S., Brousseau, M. E., Diffenderfer, M. R., Hugh, P., Barrett, P. H. R., Welty, F. K., Faruqi, A., Wolfe, M. L., Nartsupha, C., DIGENIO, A. G., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000219695.84644.56 · Cited by 64 · see citing works

Low‐density Lipoprotein Apheresis in Children With Familial Hypercholesterolemia: Follow‐up to 21 Years

Palcoux, J., Atassi, M., Lefèvre, P., et al. (2008) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2008.00574.x · Cited by 63 · see citing works

The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy

Yamamoto, A., Harada‐Shiba, M., Kawaguchi, A., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00373-7 · Cited by 58 · see citing works

Adults with Congenital Heart Disease: Psychological Needs and Treatment Preferences

Kovacs, A. H., Bendell, K. L., Colman, J. M., Harrison, J. L., Oechslin, E. N., & Silversides, C. K. (2009) · Congenital Heart Disease · doi:10.1111/j.1747-0803.2009.00280.x · Cited by 58 · see citing works

Long‐term Effect of Low‐density Lipoprotein Apheresis in Patients with Homozygous Familial Hypercholesterolemia

Makino, H., & Harada‐Shiba, M. (2003) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2003.00073.x · Cited by 50 · see citing works

Lipid and low-density-lipoprotein apheresis. Effects on plasma inflammatory profile and on cytokine pattern in patients with severe dyslipidemia

Stefanutti, C., Morozzi, C., & Petta, A. (2011) · Cytokine · doi:10.1016/j.cyto.2011.08.027 · Cited by 46 · see citing works

Homozygous familial hypercholesterolaemia

Macchiaiolo, M., Gagliardi, M. G., Toscano, A., Guccione, P., & Bartuli, A. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61476-1 · Cited by 45 · see citing works

Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography

Santos, R. D., Miname, M. H., Martinez, L. R. C., Rochitte, C. E., Chacra, A. P. M., Nakandakare, E. R., Chen, D. J., & Schaefer, E. J. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.017 · Cited by 45 · see citing works

LDL-Apheresis in Homozygous LDL-Receptor-Defective Familial Hypercholesterolemia: The Munich Experience

Keller, C. (2009) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(09)71805-7 · Cited by 43 · see citing works

LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors

Keller, C., Grützmacher, P., Bahr, F., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92542-2 · Cited by 41 · see citing works

Role of lipid apheresis in changing times

Schuff‐Werner, P., Fenger, S., & Kohlschein, P. (2012) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-012-0049-3 · Cited by 41 · see citing works

HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN THE NETHERLANDS: PREVALENCE, GENOTYPE-PHENOTYPE RELATIONSHIP AND CLINICAL OUTCOME

Sjouke, B., Kusters, D. M., Kindt, I., Besseling, J., Defesche, J. C., Sijbrands, E. J. G., van Lennep, J. E. R., Stalenhoef, A. F. H., Wiegman, A., Graaf, J. D., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(14)62053-2 · Cited by 41 · see citing works

Statins in homozygous familial hypercholesterolemia

Marais, A. D., Blom, D. J., & Firth, J. C. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0058-7 · Cited by 40 · see citing works

Fatal Myocardial Infarction at 4.5 Years in a Case of Homozygous Familial Hypercholesterolaemia

Gautschi, M., Pavlović, M., & Nuoffer, J. (2011) · JIMD Reports · doi:10.1007/8904_2011_45 · Cited by 39 · see citing works

Autosomal Recessive Hypercholesterolemia

Soutar, A. K., & Naoumova, R. P. (2004) · Seminars in Vascular Medicine · doi:10.1055/s-2004-861491 · Cited by 39 · see citing works

Aortic stenosis in homozygous familial hypercholesterolaemia.

Rallidis, L. S., Nihoyannopoulos, P., & Thompson, G. R. (1996) · Heart · doi:10.1136/hrt.76.1.84 · Cited by 39 · see citing works

Translational Lessons from a Case of Combined Heart and Liver Transplantation for Familial Hypercholesterolemia 20 Years Post-operatively

Ibrahim, M., El-Hamamsy, I., Barbir, M., et al. (2011) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-011-9311-1 · Cited by 39 · see citing works

The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: Developing a new framework for future therapies

Ooi, E. M. M., Barrett, P. H. R., & Watts, G. F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.069 · Cited by 38 · see citing works

Effects of maternal hypercholesterolemia on pregnancy and development of offspring

de Assis, S. M. A., Seguro, A. C., & Helou, C. M. B. (2003) · Pediatric Nephrology · doi:10.1007/s00467-003-1082-8 · Cited by 37 · see citing works

Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia

Shaikh, A. M. A., Abdullah, M. H., Barclay, A. R., et al. (2002) · Cardiology in the Young · doi:10.1017/s1047951102000240 · Cited by 37 · see citing works

Aorta and coronary angiographic follow‐up of children with severe hypercholesterolemia treated with low‐density lipoprotein apheresis

Stefanutti, C., Vivenzio, A., Giacomo, S. D., Mazzarella, B., Bosco, G., & Berni, A. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02135.x · Cited by 36 · see citing works

Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia

Tevfik, K., Yankol, Y., Kanmaz, T., et al. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2010.01469.x · Cited by 36 · see citing works

Phenotype of Heterozygotes for Low-Density Lipoprotein Receptor Mutations Identified in Different Background Populations

Tybjærg‐Hansen, A., Jensen, H. K., Benn, M., Steffensen, R., Jensen, G. B., & Nordestgaard, B. G. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000149380.94984.f0 · Cited by 35 · see citing works

Low Density Lipoprotein Apheresis in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Çöker, M., Uçar, S. K., Şimşek, D. G., et al. (2009) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2009.00666.x · Cited by 31 · see citing works

Homozygous familial hypercholesterolemia: Long term clinical course and plasma exchange therapy for two individual patients and review of the literature

Beigel, R., & Beigel, Y. (2009) · Journal of Clinical Apheresis · doi:10.1002/jca.20215 · Cited by 26 · see citing works

Liver transplantation as treatment for familial homozygous hypercholesterolemia: Too early or too late

Malatack, J. J. (2011) · Pediatric Transplantation · doi:10.1111/j.1399-3046.2010.01458.x · Cited by 26 · see citing works

Surgical strategies for severe calcifications of the aorta (porcelain aorta) in two patients with homozygous familial hypercholesterolemia

Grenon, S. M., Lachapelle, K. J., Marcil, M., et al. (2007) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(07)70889-9 · Cited by 19 · see citing works

Cerebral cholesterol granuloma in homozygous familial hypercholesterolemia

Francis, G. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041152 · Cited by 19 · see citing works

Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial

Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R. C., Wasserman, S. M., & Stein, E. A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.004 · Cited by 17 · see citing works

Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis

Dann, E. J., Shamir, R., Mashiach, T., et al. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.05.001 · Cited by 15 · see citing works

Aortic Root Involvement in Homozygous Familial Hypercholesterolemia—Transesophageal Echocardiographic Appearances of Supravalvular Aortic Stenosis

Koh, T. W. (2005) · Echocardiography · doi:10.1111/j.1540-8175.2005.00123.x · Cited by 13 · see citing works

Supra-valvular aortic stenosis in a patient with homozygous familial hypercholesterolaemia

Rajendran, R., Srinivasa, K. H. S., Rangan, K., et al. (2013) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jet072 · Cited by 10 · see citing works

The lower the better: Target values after LDL-Apheresis and semi-selective LDL-elimination therapies

Borberg, H. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.03.009 · Cited by 4 · see citing works

PO23-764 TORCETRAPIB/ATORVASTATIN SUBSTANTIALLY RAISES HDL-C AND MARKEDLY LOWERS LDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Raal, F. J., Marais, A. D., Gagné, C., et al. (2007) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(07)71774-9 · Cited by 4 · see citing works

Successful treatment of homozygous familial hypercholesterolemia using cascade filtration plasmapheresis

Kardaş, F., Çetin, A., Solmaz, M., et al. (2011) · Turkish Journal of Hematology · doi:10.5152/tjh.2011.20 · Cited by 3 · see citing works

PO23-767 THE EFFECT OF ATORVASTATIN TREATMENT ON SERUM LEVELS OF LIPIDS AND C-REACTIVE PROTEIN IN PATIENTS WITH ACUTE CORONARY SYNDROME

Vertkin, A. L. (2007) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(07)71777-4 · Cited by 1 · see citing works

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works

Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database

Nguengang Wakap, S., Lambert, D. M., Olry, A., Rodwell, C., Gueydan, C., Lanneau, V., Murphy, D., Le Cam, Y., & Rath, A. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-019-0508-0 · Cited by 1,752 · see citing works

Interpretation of the evidence for the efficacy and safety of statin therapy

Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · see citing works

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works

Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979 · see citing works

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891 · see citing works

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw152 · Cited by 847 · see citing works

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818 · see citing works

Evinacumab for Homozygous Familial Hypercholesterolemia

Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793 · see citing works

Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575 · see citing works

2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Daly, D. D., DePalma, S. M., Minissian, M. B., Orringer, C. E., & Smith, S. C. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.519 · Cited by 459 · see citing works

Interaction between Glucose and Lipid Metabolism: More than Diabetic Dyslipidemia

Parhofer, K. G. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.353 · Cited by 458 · see citing works

Chylomicronaemia–current diagnosis and future therapies

Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356 · see citing works

ANGPTL3 inhibition in homozygous familial hypercholesterolemia

Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323 · see citing works

The Evolving Future of PCSK9 Inhibitors

Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264 · see citing works

Genetics of hypertriglyceridemia

Dron, J. S., & Hegele, R. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00455 · Cited by 244 · see citing works

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204 · see citing works

Lipid-Lowering Agents: Targets Beyond PCSK9

Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171 · see citing works

National lipid association annual summary of clinical lipidology 2016

Bays, H. E., Jones, P. H., Orringer, C. E., Brown, W. V., & Jacobson, T. A. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.002 · Cited by 128 · see citing works

Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs · doi:10.1007/s40265-019-01114-z · Cited by 132 · see citing works

Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Hovingh, G. K., Lepor, N. E., Kallend, D., Stoekenbroek, R. M., Wijngaard, P. L. J., & Raal, F. J. (2020) · Circulation · doi:10.1161/circulationaha.119.044431 · Cited by 113 · see citing works

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab

Thedrez, A., Blom, D. J., Ramin-Mangata, S., Blanchard, V., Croyal, M., Chemello, K., Nativel, B., Pichelin, M., Cariou, B., Bourane, S., et al. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310217 · Cited by 105 · see citing works

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity

Banerjee, P., Chan, K.-C., Tarabocchia, M., Benito-Vicente, A., Alves, A. C., Uribe, K. B., Bourbon, M., Skiba, P. J., Pordy, R., Gipe, D. A., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.313051 · Cited by 97 · see citing works

Mipomersen and its use in familial hypercholesterolemia

Parham, J. S., & Goldberg, A. C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1550071 · Cited by 94 · see citing works

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

Krähenbühl, S., Pavik-Mezzour, I., & von Eckardstein, A. (2016) · Drugs · doi:10.1007/s40265-016-0613-0 · Cited by 89 · see citing works

<scp>PCSK9</scp> inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

Baum, S. J., Toth, P. P., Underberg, J. A., Jellinger, P., Ross, J., & Wilemon, K. (2017) · Clinical Cardiology · doi:10.1002/clc.22713 · Cited by 88 · see citing works

PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016

Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86 · see citing works

&lt;p&gt;Lomitapide: a review of its clinical use, efficacy, and tolerability&lt;/p&gt;

Alonso, R., Cuevas, A., & Mata, P. (2019) · Core Evidence · doi:10.2147/ce.s174169 · Cited by 81 · see citing works

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From <i>ATVB</i> Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · see citing works

Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices

Thongtang, N., Sukmawan, R., Llanes, E. J. B., & Lee, Z.-V. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101819 · Cited by 61 · see citing works

Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases

Pirillo, A., L. Catapano, A., & D. Norata, G. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160229114111 · Cited by 45 · see citing works

An assessment of clinical characteristics of patients with ASCVD, ASCVD-risk equivalent (both with hypercholesterolemia) and familial hypercholesterolemia: A real-world database analysis in England

Seshagiri, D., Lahoz, R., Achouba, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.772

Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia

Mizuta, M. H., & Santos, R. D. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.006

Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician?

Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000391 · Cited by 18 · see citing works

Role Of Innate And Adaptive Immunity On Atherosclerosis In Subjects With Familial Hypercholesterolemia

Fonzar, W. T., Fonseca, F. A. H., Fonseca, H. A. R., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.116

Effect of causative genetic variants on atherosclerotic cardiovascular disease in heterozygous familial hypercholesterolemia patients

Matta, A. G., Rabès, J., Taraszkiewicz, D., et al. (2025) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.10.283